Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer;153Samarium-EDTMP et contrôle de la douleur liée aux métastases osseuses des cancers bronchiques

Revue des Maladies Respiratoires

Volumn 22, Issue 2 C1, 2005, Pages 317-320

  Ratsimanohatra, H ^a   Barlesi, F ^b,c,d   Doddoli, C ^b   Robitail, S ^d   Gimenez, C ^b   Kleisbauer, J P ^b   Astoul, P ^b  

^a CHU Antananarivo   (Madagascar)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Hopitaux Sud AP HM   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

153Sm EDTMP; Bone metastasis; Lung cancer; Quadramet; Radiopharmaceutical

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; LEXIDRONAM SAMARIUM SM 153; MORPHINE; NAVELBINE; OPIATE; PACLITAXEL; PAMIDRONIC ACID; RADIOPHARMACEUTICAL AGENT; STEROID; ANALGESIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ADULT; ANALGESIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PATIENT; CLINICAL ARTICLE; DATA ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; MALE; OUTCOMES RESEARCH; PALLIATIVE THERAPY; TREATMENT OUTCOME; VISUAL ANALOG SCALE; AGED; BONE TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PAIN; PATHOLOGY;

AGED; ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN;

EID: 18744415182     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1019/200539978     Document Type: Article

References (12)

1. Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, Bazelly B, Brechot JM, Breton JL, Douillard JY, Grivaux M, Jacoulet P, Khalil A, Lemarie E, Martinet Y, Massard G, Milleron B, Molina T, Moro-Sibilot D, Paesmans M, Pujol JL, Quoix E, Ranfaing E, Riviere A, Sancho-Garnier H, Souquet JP, Spaeth D, Stoebner-Delbarre A, Thiberville L, Touboul E, Vaylet F, Vergnon JM, Westeel V: Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients. Bull Cancer 2003; 90: 151-66.
2. Kvale PA, Simoff M, Prakash UB: American College of Chest Physicians. Lung cancer. Palliative care. Chest 2003; 123: 284S-311S.
3. Roque M, Martinez M, Alonso P, Catala E, Garcia J, Ferrandiz M: Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2003; 4: CD003347.
4. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D: A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33: 1583-91.
5. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-81.
6. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ: Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999; 26: 2-7.
7. Deng H, Luo S, Tan T, Mo T, Liang Z, Pu M, Jiao J, Zhong S, Wang Q, Hu Y: 153Sm-EDTMP for moderate and severe bone cancer pain. Hua Xi Yi Ke Da Xue Xue Bao 1995; 26: 391-4.
8. Tian J, Cao L, Zhang J, Ouyang Q, Hou Q, He Y: Comparative analysis of patients not responding to a single dose of 153Sm-EDTMP palliative treatment for painful skeletal metastases. Chin Med J (Engl) 2002; 115: 824-8.
9. Murai N, Koga K, Nagamachi S, Nishikawa K, Matsuki K, Kusumoto S, Watanabe K: Radiotherapy in bone metastases - with special reference to its effect on relieving pain. Gan No Rinsho 1989; 35: 1149-52.
10. Silberstein EB: Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000; 10: 240-9.
11. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patti P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R: Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002; 8: 1781-807.
12. Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA: A phase I radioimmunotherapy trial evaluating 90yttrium-labeled and-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000; 6: 3855-63.